Az új, napi egy alkalommal adagolható 5-aminoszalicilsav- készítmények hatékonysága colitis ulcerosában

Translated title of the contribution: Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents is commercially available, including azo-bond pro-drugs such as sulfasalazine, olsalazine and balsalazide, and delayed- and controlled-release forms of mesalazine. In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets. Furthermore, poor adherence has been shown to be an important barrier to successful management of patients with UC. Recently, new, once-daily formulations of mesalazine including the unique multi-matrix delivery system and mesalazine granules were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of low pill burden and may contribute to increased long-term compliance and treatment success in clinical practice and might potentially further contribute to a decline in the risk for UC-associated colon cancers. In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.

Translated title of the contributionEffectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis
Original languageHungarian
Pages (from-to)397-404
Number of pages8
JournalOrvosi hetilap
Volume150
Issue number9
DOIs
Publication statusPublished - Mar 1 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this